Synlogic, Inc. (SYBX)

Market Cap	16.90M
Revenue (ttm)	2.78M
Net Income (ttm)	-37.18M
Shares Out	11.70M
EPS (ttm)	-3.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,177
Open	1.396
Previous Close	1.360
Day's Range	1.396 - 1.445
52-Week Range	1.220 - 5.120
Beta	0.84
Analysts	Buy
Price Target	15.50 (+972.81%)
Earnings Date	Nov 12, 2024

About SYBX

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat hom...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Antoine Awad
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: SYBX
• Website: https://www.synlogictx.com

Financial Performance

In 2023, Synlogic's revenue was $3.37 million, an increase of 185.68% compared to the previous year's $1.18 million. Losses were -$57.28 million, -13.40% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for SYBX stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 972.81% from the latest price.

Price Target

$15.5

(972.81% upside)

Analyst Consensus: Buy